Neurocrine Biosciences | NBIX - Рыночная капитализация





Рыночная капитализация Изменить Дата
AbbVie USD 355.2B 48.64B 2026-04
Acadia Pharmaceuticals USD 4.52B 919M 2025-12
Agios Pharmaceuticals USD 1.53B 57M 2026-04
ALKERMES USD 4.62B 333M 2025-12
Alnylam Pharmaceuticals USD 52.54B 7.24B 2025-12
Amgen USD 176.25B 24.32B 2025-12
Biogen USD 27.49B 589M 2026-04
BioMarin Pharmaceutical USD 11.42B 1.02B 2025-12
Cytokinetics USD 7.77B 1.19B 2025-12
Enanta Pharmaceuticals USD 122M 98M 2024-12
Exelixis USD 11.75B 959M 2025-12
Gilead Sciences USD 166.62B 14.34B 2026-04
Halozyme Therapeutics USD 7.91B 664M 2025-12
Incyte USD 21.96B 3.23B 2026-04
Ionis Pharmaceuticals USD 10.55B 1.91B 2026-04
Nektar Therapeutics USD 14.34B 13.48B 2026-04
Neurocrine Biosciences USD 14.14B 218M 2025-12
Pfizer USD 141.57B 6.48B 2025-12
Prothena USD 514M 11M 2025-12
Regeneron Pharmaceuticals USD 75.46B 6.22B 2026-04
Repligen USD 9.22B 1.7B 2025-12
Sarepta Therapeutics USD 2.26B 238M 2025-12
Teva Pharmaceutical Industries USD 107.27B 72.99B 2026-04
Ultragenyx Pharmaceutical USD 2.22B 680M 2025-12
Vertex Pharmaceuticals USD 115.03B 14.61B 2025-12